Argus Partners advises Mynvax in raising $4.2 million to introduce 'warm vaccine' to market

Argus Partners advised Mynvax, a vaccine technology startup, when it raised approximately $4.2 million in its Series A funding round led by Accel and other investors. Mynvax is developing novel recombinant vaccines for covid-19 and human influenza and will use the proceeds in further clinical developments.The Argus Team was led by Vinod...